China-based Sitoa Global is making some big moves after landing an exclusive licensing contract with UC San Francisco, according to a company announcement.

Sitoa signed an exclusive letter of intent for UCSF’s "medical stereotactic device," designed to streamline the therapeutic delivery of stem cells into the brain.

In anticipation of the agreement, Sitoa is undergoing some massive restructuring, getting rid of all of its e-commerce and software businesses in order to focus on the deal ahead of what the company described as a "gold rush."

"The stem cell industry is one of the fastest growing and most compelling areas in medicine with numerous companies and research institutions spending hundreds of millions of dollars per year on the development of new therapies and devices," according to a Sitoa press release. "The company believes that the device could become the preferred tool for the deployment of stem cells into the human brain for any company or clinician conducting clinical trials and providing experimental treatment in this field. Therefore, the use of the device could become analogous to the use of ‘picks and shovels’ during the historical gold rush and allow the company to pursue such a picks-and-shovels business model and to participate in the growth of the stem cell industry as a provider of tools and resources."